The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
about
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisUpper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug useA novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataThe efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials.Prevention of hip fractures in long-term care: relevance of community-derived data.Preventing fractures in elderly people.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisEvidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubOnce-monthly risedronate for postmenopausal osteoporosis2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisModeling the benefits of pamidronate in children with osteogenesis imperfecta.Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.Differences between the bisphosphonates for the prevention and treatment of osteoporosis.Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability.Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.An approach to postmenopausal osteoporosis treatment: a case study review.Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model.Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities.Ibandronate: a clinical pharmacological and pharmacokinetic update.Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulationManagement of age-related osteoporosis and prevention of associated fractures.Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosisEvidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.Medical treatment of osteoporotic vertebral fractures.Discovery, clinical development, and therapeutic uses of bisphosphonates.Risedronate for prevention and treatment of osteoporosis in postmenopausal women.Bisphosphonates for the treatment of osteoporosis: insights for clinicians.Canadian Consensus Conference on osteoporosis, 2006 update.How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.Developments in the pharmacotherapeutic management of osteoporosis.Drug insight: Bisphosphonates for postmenopausal osteoporosis.Drug insight: Existing and emerging therapies for osteoporosis.Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
P2860
Q24242674-8026385E-765E-4FCE-96F7-56B2990BE39CQ24644708-003A23EC-8A67-4CDC-B333-5D32592224CEQ24680238-3725F756-3BE7-4AE9-9867-A1BE156194B9Q28218365-70C4097F-9D90-4FF0-9E1E-3CB33D80F067Q30577427-C30C893B-39BC-4DB8-A024-CBA00217590FQ30967433-38C4FA47-5136-4FB5-9B21-965A014935E3Q31162221-78F71BD7-A12F-473A-8E99-4C0F88D7E9C8Q33546626-F4B1A1DF-AFB5-4807-843C-3EBC96E556DAQ33815676-770A0F3B-C730-42FD-98BF-04D8DF2DE182Q34042003-7BEE6E65-4FAE-4B06-B644-6C0A9FB3964EQ34099162-29C7822E-D390-43FE-AE3A-D8ECD8E556AEQ34272000-EDBF0C71-35F9-4978-A344-37883AA7DD92Q34300668-456E3BE8-AFF8-4B4A-A8E1-964EF73F35F4Q34323496-B5236C54-A3F6-433E-B61B-DDF039F5E0C6Q34658660-0A0DDE54-A515-45A7-A876-6CD61377A188Q34816036-8F0EFC9C-511B-4EA5-9218-D07E4A654318Q35026446-25C72AEC-0D24-448F-823B-66DF2BB03068Q35166767-0311FF2B-6147-4800-92BD-622C85BCFE86Q35188424-EB48E89D-AC33-4496-91FF-02F1F90FEA48Q35644131-CBDE03A5-80F7-4E9F-8C06-4B2C4708982CQ35675259-0394F18E-F2F9-4438-8048-D308457A35A2Q35678676-683B7352-59A0-493E-9B69-C8887E3A645BQ35767240-25FE3A58-F2EE-484B-835C-9BE4559DA0CEQ35775369-02FBA663-077E-40FB-8311-376EC1B2A81CQ35866199-CFDDA396-4922-44CA-B9B5-AE81E5EC58A8Q35905973-1C6F0307-3B76-44E5-BD7A-F989F1F55408Q35919125-95D7B4F5-487A-4167-BFB1-4CD59B2339D3Q35954529-4BF16BAB-7797-4B69-B92D-9115457726F4Q35963011-85FAC0AC-9A19-4E09-B1A4-FA1A2B12EBA6Q36056975-EAC2F763-D034-4929-81B1-41DFDAF1E7A2Q36059589-7B4C0C91-7DBA-4268-B97D-07D604E8F34EQ36065420-0ED6DA7E-9E88-44CF-9356-A21E0D045ABDQ36082078-E89D4A76-3A71-4CA0-9491-303979F6ADD4Q36443681-5B164203-409A-447E-8300-47C7237964D5Q36454421-CE1665BB-4742-4538-B3F5-0E46391DD394Q36492900-1886A7F4-556F-41AF-B021-38BADB951DEEQ36548722-BEE7C2C6-0DB2-4FBA-833C-F2B8E0CB8AE2Q36576992-20D542D4-A606-411A-B1E2-9EC462A1E689Q36672697-7BFDCB96-1FEF-4E01-B27C-6DE665908E1CQ36897425-AD377546-5372-452F-8587-2C6A33014476
P2860
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The efficacy and tolerability ...... f postmenopausal osteoporosis.
@en
The efficacy and tolerability ...... f postmenopausal osteoporosis.
@nl
type
label
The efficacy and tolerability ...... f postmenopausal osteoporosis.
@en
The efficacy and tolerability ...... f postmenopausal osteoporosis.
@nl
prefLabel
The efficacy and tolerability ...... f postmenopausal osteoporosis.
@en
The efficacy and tolerability ...... f postmenopausal osteoporosis.
@nl
P2093
P1476
The efficacy and tolerability ...... f postmenopausal osteoporosis.
@en
P2093
Bolognese MA
Kendler DL
P2888
P304
P356
10.1007/S00223-002-2011-8
P407
P577
2002-06-27T00:00:00Z